Gastroparesis Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Gastroparesis Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The gastroparesis drug market is expected to register a CAGR of 4.5% over the forecast period (2022-2027).

The healthcare sector had witnessed a significant impact of COVID-19 impact. In patients with chronic Gastroinstentinal illnesses, COVID-19 may initially present as a flare of their underlying GI conditions as viruses have historically been implicated in exacerbations of Gastroinstentinal disorders, including gastroparesis. Moreover, according to the world gastroenterology organization factsheet published in September 2020, there has been observed a rise in gastrointestinal complications after COVID-19 symptoms. Patients with COVID-19 may complain of digestive symptoms such as poor appetite, nausea, vomiting, diarrhea, symptoms, or disease activity for pre-existing digestive diseases such as inflammatory bowel disease. However, according to a review of Diabetic Gastroparesis for the Community Pharmacist published in February 2020, over 44 million people in the United States have diabetes and have faced complications associated with the disease. Similarly, even after the pandemic, As per the national library of medicine studies published in October 2021, Even after recovering from COVID, many patients are experiencing loss of appetite or increased appetite, upper abdominal pain, acidity, diarrhea, and vomiting, and these issues can become more serious if not treated at the right time. Complete evaluation, monitoring, and healing are required for recovery. The same source revealed that COVID-19 affects the Gastroinstentinsal tract too. It disrupts its functioning and renders it unable to perform its duties of absorbing electrolytes and fluids from the body. Patients can even end up with bleeding in the gastrointestinal tract. Thus, COVID-19 can be responsible for increasing the complications of gastroparesis. Thu, the covid-19 has had a significant impact on market growth.

Diabetes is the most common systemic disease that causes gastroparesis. Moreover, according to data published by the National Center for Biotechnology Information (NCBI) in September 2020, nausea and vomiting from detailed consideration as symptoms of COVID19 is surprising as they can be early presenting symptoms. Thus, there has been observed a rise in the sale of prokinetic agents and antiemetic agents. However, due to disruption in the supply chain and governmental orders restricting certain activities in response to COVID-19, including changes in on-site operations to reduce manufacturing capacity and implement social distancing, reductions in suppliers’ ability to source, ship raw materials in alignment with demands, work stoppages, slowdowns, and delays, the market may show a slowdown. Thus, COVID-19 has made a significant impact on the market.

Several factors, such as the increase in the incidence rate of the diabetic population, rise in the number of surgical procedures, and growth in the geriatric population are among the key driving factors for the gastroparesis drug market. Gastroparesis is a disorder affecting mostly type1 and type2 diabetic patients. In this disorder, the stomach takes too long to empty its contents. Drugs, such as erythromycin, antiemetics, and Reglan are prescribed for treating gastroparesis. Moreover, there are 119 completed and ongoing clinical trials for gastroparesis drugs due to the high prevalence of type1 type2 diabetes which may further have high chances of having gastroparesis. This drives the demand for these drugs and will further fuel the overall market to a certain extent. For instance, as per the data published by the national library of medicine in October 2020, In an epidemiologic study from Europe, the estimated overall prevalence of gastroparesis drugs was 13.8 per 100,000 persons with an incidence of 1.9 per 100,000 person-years. Overall survival was significantly lower in patients with diabetes and those with gastroparesis than for the age- and the sex-matched general population. Thus, the increasing cases of gastroparesis are driving the growth of the market.

Furthermore, leading manufacturers are continuously funding research and development (R&D) projects to introduce new approaches to the existing drug therapy. They are also developing advanced and effective drugs that can be administered via the nasal cavity for individuals who are experiencing symptoms of gastroparesis, which is creating a favorable market outlook. For instance, a pilot study presented at the 2020 annual meeting of the North American Neuromodulation Society assessed the effectiveness of the gammaCore hand-held vagal nerve stimulator for the treatment of gastroparesis. Gastric Per-Oral Endoscopic Pyloromyotomy (GPOEM) is a safe and effective therapy for refractory gastroparesis. For instance, researchers from Emory University (U.S) assessed the safety and efficacy of GPOEM and compared clinical outcomes between diabetic and non-diabetic cohorts, and found that patients with predominant nausea/vomiting and short duration of diabetic gastroparesis may opt for GPOEM. While the time-consuming regulatory process and side effects of gastroparesis drugs are witnessed to hamper the growth of the market during the forecast period.

Key Market TrendsIdiopathic Gastroparesis Segment is Expected to Contribute a largest segment in the Gastroparesis Drug Market.

Idiopathic gastroparesis is growing at a good rate as this disease is a very common category in gastroparesis, wherein the cause is unknown and symptoms are vomiting, nausea, and upper abdominal pain. These symptoms can be cured by dietary modification, antiemetic drug therapy, prokinetics medication, and symptoms modulators. This further results in the adoption of gastroparesis drugs and will drive the market to a certain extent. Prokinetics drugs will also enhance gastrointestinal motility by increasing the frequency of contraction and propel the growth of the gastroparesis drug market.

In addition, the growing diabetes Mellitus population worldwide, leading to high demand for diagnosis and treatment, and diabetes is a common cause of gastroparesis condition, thus propelling the gastroparesis drug market.

As per the study published by the national organization for rare disorders in December 2020, Gastroparesis demonstrates a gender bias affecting more women than men. Approximately 80% of idiopathic cases are women. Idiopathic gastroparesis may be linked to an as yet-to-be-elucidated enteric autoimmune disease. The prevalence of delayed gastric emptying in Type 1 diabetics has been reported to be 50% and in type 2 diabetics, reports range from 30% to 50%. Post surgical gastroparesis is a recognized as inadvertent vagal nerve damage or entrapment following upper abdominal surgery, examples are: fundoplication for the treatment of GERD, bariatric surgery, peptic ulcer surgery, anterior approach for spinal surgery (scoliosis), heart, lung transplant, or pancreatic surgery. Thus, the increasing prevalence of Idiopathic Gastroparesis are driving the growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the gastroparesis drug market due to the increasing aging population and the rising number of surgical procedures. The United States dominated the market owing to a large prediabetic population and favorable reimbursement policies. For instance, according to the Centers for Disease Control and Prevention in 2021, 96 million people aged 18 years or older have prediabetes (38.0% of the adult United States population). Furthermore, increasing healthcare expenditure, a growing number of hospitals, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Additionally, the High per capita income and increasing healthcare spending are among the key factors driving its market. According to American Diabetes Association, in 2020, the average estimated cost of diabetes-specific treatments per person was USD 9,505.60. In the United States, a prediabetic patient can incur an overall medical expenditure of nearly USD 16,750 per year. Thu the high per capita income and increasing healthcare spending are propelling the market growth.

The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding prediabetes care in the region. In January 2020, Novo Nordisk announced that the United States Food and Drug Administration (FDA) had approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes. Such developments are expected to increase the sales of Fiasp during the forecast period.

Competitive Landscape

The market is consolidated in nature due to the presence of various players operating globally. Some of the companies which are currently dominating the market are Abbott Laboratories (Abbott Arzneimittel GmbH), AbbVie Inc. (Allergan Plc), Cadila Pharmaceuticals, Evoke Pharma, AstraZeneca Plc, Neurogastrx Inc., Bausch Health, Theravance Biopharma, and GlaxoSmithKline Plc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.